Biomarkers in cardiovascular medicine (Q37500635)

20 August 2017

1 reference

title

Biomarkers in cardiovascular medicine (English)

1 reference

20 August 2017

0 references

1 reference

0 references

José L Martín-Ventura

1

1 reference

20 August 2017

Luis M Blanco-Colio

2

1 reference

20 August 2017

José Tuñón

3

1 reference

20 August 2017

Begoña Muñoz-García

4

1 reference

20 August 2017

Julio Madrigal-Matute

5

1 reference

20 August 2017

Juan A Moreno

6

1 reference

20 August 2017

Melina Vega de Céniga

7

1 reference

20 August 2017

Jesús Egido

8

1 reference

20 August 2017

1 June 2009

1 reference

Revista Española de Cardiología

20 August 2017

1 reference

20 August 2017

62

1 reference

20 August 2017

6

1 reference

20 August 2017

677-688

1 reference

Mortality by cause for eight regions of the world: Global Burden of Disease Study

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Quest for novel cardiovascular biomarkers by proteomic analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Soluble P-selectin and the risk of future cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Circulating cell adhesion molecules and death in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titrati

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Inflammatory markers and onset of cardiovascular events: results from the Health ABC study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Increasing Levels of Interleukin (IL)-1Ra and IL-6 During the First 2 Days of Hospitalization in Unstable Angina Are Associated With Increased Risk of In-Hospital Coronary Events

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

C-reactive protein and coronary heart disease: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

C-reactive protein predicts death in patients with previous premature myocardial infarction--a 10 year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

C-reactive protein as a predictor of cardiac rupture after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

C-reactive protein levels and outcomes after statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Lipoprotein-associated phospholipase A2: a risk marker or a risk factor?

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Low plasma levels of HSP70 in patients with carotid atherosclerosis are associated with increased levels of proteolytic markers of neutrophil activation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Thrombolytic therapy of acute myocardial infarction alters collagen metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

CD40 signaling and plaque instability

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Soluble CD40L and cardiovascular risk in women

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Soluble CD40 Ligand in Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Soluble CD40L: risk prediction after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Metalloproteinase-mediated release of human Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Levels of soluble Fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease: a novel biomarker of endothelial function?

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Role of heat shock proteins in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Heat shock proteins, inflammation, and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Circulating heat shock protein 60 is associated with early cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Helicobacter pylori heat shock protein 60 and risk of coronary heart disease: a case control study with focus on markers of systemic inflammation and lipids

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Circulating human heat shock protein 60 in the plasma of British civil servants: relationship to physiological and psychosocial stress

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Elevated heat shock protein 60 levels are associated with higher risk of coronary heart disease in Chinese

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Increased serum levels of heat shock protein 70 are associated with low risk of coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Plasma concentration of heat shock protein 27 and risk of cardiovascular disease: a prospective, nested case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Cytokine-receptor pairing: accelerating discovery of cytokine function

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

The TNF and TNF receptor superfamilies: integrating mammalian biology

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

The molecular architecture of the TNF superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Identification of a ligand for the death-domain-containing receptor Apo3

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2809%2972232-7

7 January 2021

10.1016/S1885-5857(09)72232-7

Identifiers

DOI

0 references

1 reference